AI cardiac diagnostics to skyrocket in 2036. Investing in healthcare's next frontier. Well, if you've been keeping an eye on where healthcare's dollars are heading, take note: AI-driven cardiac diagnostics is taking the lead, and it's set to make some noise in the investment circles. Investors Hangout, LLC is talking a jump from USD 903.2 million in 2026 to a staggering USD 2,805.1 million by 2036. That's a 12.0% CAGR, and it's not just smoke - it's the real deal driven by numbers and need. Why AI in cardiac diagnostics? Let's break it down. Investors Hangout, LLC is seeing hospitals and clinics going all-in on AI because heart disease isn't slowing down, folks. It's on a bull run, and traditional methods just aren't cutting the mustard anymore. Artificial intelligence offers a way to speed up the process - think faster ECG interpretations and smarter imaging analysis. The tech isn't just flashy; it improves outcomes and prioritizes cases that matter. Healthcare systems are feeling the pressure, big time. More heart patients, not enough specialists, and complex monitoring needs make AI an attractive proposition. It's not just about saving time; it's about saving lives. Key players and competitive edge. So, who's neck-deep in this AI revolution? Heavyweights like GE HealthCare, Philips, and upstarts like Eko Health and AliveCor are in the race. It's all about who delivers high-performance algorithms and can achieve clinical validation. Not an easy game, but one worth watching if you're the investing type. "Companies that combine validated algorithms with scalable deployment models will better position themselves for long-term growth." - Anurag Sharma, Principal Analyst at Future Market Insights Leading segments: who benefits most? * Technology: Machine learning is owning 30.5% of the market. It's the magic sauce that analyzes ECG data and improves prediction accuracy - a hot ticket in the cardiology world. * Applications: Arrhythmia Detection is leading the charge with 31.4% market share. Given the massive amount of ECG data from various sources - hospitals, outpatient centers, remote monitoring - AI tools for identifying irregularities are crucial. * End Users: Hospitals are not just observers in this space. They hold a solid 33.5% market share. Their resources make them prime adopters of AI platforms to boost workflow and sync departments like cardiology, radiology, and ER. Tech deployment: cloud dominates. Then there's the cloud, holding a whopping 64.0% of market designs from 2026. It's about scalability and ease of management. But don't get complacent; there's more complexity beneath the surface. Providers want it secure, seamless, and reliable - or they're not buying. Geographic growth: south Korea in the spotlight. Let's talk geography, folks. South Korea is striding ahead with a 13.4% CAGR. With connected hospital networks and a big push toward digital healthcare, this country is not just filling counts - it's filling bank accounts. The USA's advanced infrastructure helps it ride closely with a 12.8% growth rate. As for Europe? Germany and the UK are stepping up thanks to digital overhauls, and Japan faces its aging population dilemma with innovation. Future Market Insights: shaping strategy. Looking to strategize your next move? Future Market Insights isn't just about numbers. Their research turns market complexity into opportunities, allowing leadership teams to identify growth opportunities faster while reducing uncertainties. To summarize. If you're contemplating where health tech is heading in the next decade, pay attention. AI-driven cardiac diagnostics is set to double in size as the healthcare world demands more speed, efficiency, and data-driven insights. Be it cloud solutions or smarter algorithms, those ready to tackle this frontier will find a market ripe for investment and innovation.

Diathrive Health and KardiaComplete announce strategic partnership to address cardiometabolic risk. GlobeNewswire | AliveCor Inc. Yesterday at 10:17am PDT MOUNTAIN VIEW, Calif., May 06, 2026 (GLOBE NEWSWIRE) - Diathrive Health, the leader in chronic disease management, and AliveCor, the global leader in AI-powered cardiology, today announced a strategic partnership to deliver a more comprehensive approach to cardiometabolic care for employers. The collaboration brings together Diathrive Health's diabetes management platform and KardiaComplete's virtual cardiovascular care solutions to address the close link between Type 2 diabetes and cardiovascular disease. Diathrive Health provides unlimited diabetes testing supplies, personalized guidance from clinically trained health advisors, and real-time data insights to support long-term behavior change. KardiaComplete offers FDA-cleared, medical-grade EKG devices, along with virtual heart health programs designed to detect and manage conditions such as atrial fibrillation and hypertension. "Diabetes and heart disease are deeply connected, yet too often they're managed separately," said Michael Hennessy, CEO of Diathrive Health. "By partnering with KardiaComplete, we're giving employers a more coordinated way to support people living with diabetes while proactively addressing cardiovascular risk. This collaboration reflects our shared commitment to improving outcomes through engagement, innovation, and truly integrated care." People living with Type 2 diabetes face a significantly higher risk of cardiovascular disease. However, many digital health solutions address these conditions separately, creating fragmented experiences for employers and members. "Cardiovascular risk doesn't exist in isolation, and neither should care," said Ed Daley, GM and SVP, Employer and Strategic Alliances at AliveCor. "Our partnership with Diathrive Health brings together proactive diabetes management and virtual cardiovascular care to help employers identify risk earlier and support members more holistically. Together, we're advancing a more connected approach to cardiometabolic health." Through this partnership, the companies will align their platforms to provide a more unified cardiometabolic solution. The initial focus is on the employer market, where the organizations will collaborate on sales efforts and coordinate implementation and member-engagement strategies. The partnership is designed to support employers seeking more integrated approaches to chronic condition management. For more information visit kardiacomplete.com or diathrive.com. About Diathrive Health Founded in 2017 and headquartered in Salt Lake City, Diathrive Health is a leading provider of comprehensive health solutions, focused on diabetes management and GLP-1 medication optimization. Diathrive delivers a proven diabetes solution that includes unlimited supplies, personalized care from clinical experts (RN, RD, and CDCES), and industry-leading engagement, helping employers reduce diabetes-related plan spend by up to 85%. The GLP-1 weight loss management solution incorporates hands-on physician oversight and a rigorous qualification strategy to ensure appropriate use, lower cost, and a strong return on investment (ROI) for health plans by driving sustainable weight loss. Diathrive Health is committed to driving better health outcomes and significant savings for employers and their members. Media Contact Morgan Mathis Director of Corporate Communications, AliveCor [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.